Paclitaxel Protein-Bound (Paclitaxel)

Generic Name

Paclitaxel

Brand Names

Paclitaxel Protein-Bound, Abraxane

FDA approval date: March 01, 2004

Classification: Microtubule Inhibitor

Form: Injection

What is Paclitaxel Protein-Bound (Paclitaxel)?

Paclitaxel protein-bound particles for injectable suspension is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Who is this study for: Patients with PD-L1-negative, advanced non-small cell lung cancer

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Other, Procedure, Biological, Radiation

Study Drugs: Carboplatin, Ipilimumab, Nab-paclitaxel, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed

Study Phase: Phase 2/Phase 3

Summary: This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary s...

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Who is this study for: Adult patients with non-small cell lung squamous cell carcinoma

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium

Study Phase: Phase 3

Summary: This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ch...

A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Phase: Phase 3

Summary: This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in differen...

View All Clinical Trials